Iron Overload Management in Thalassemia

Transfusion‑Dependent Thalassemia Major

Each unit of transfused blood delivers ≈ 200 mg of elemental iron, causing rapid accumulation that necessitates lifelong iron‑chelation therapy. 1, 2, 3
Serum ferritin is usually markedly elevated; values > 1 000 ng/mL reliably indicate clinically significant iron overload in this population. 4, 5
Oral or parenteral iron supplementation is absolutely contraindicated; adding iron worsens overload and accelerates organ damage. 6
Management should focus on initiating or intensifying iron‑chelation regimens rather than providing supplemental iron. 1, 2

Cardiac iron deposition is the leading cause of mortality in transfusion‑dependent thalassemia, accounting for roughly 70 % of deaths even when chelation therapy is employed. 4, 1, 5
Unchecked iron overload markedly increases the risk of heart failure, liver disease, endocrine dysfunction, osteopenia, and malignancy. 4, 5

Microcytic anemia in thalassemia patients reflects the underlying hemoglobin synthesis defect, not iron deficiency; therefore routine iron supplementation is inappropriate. 1, 2
Providing iron to patients who are already iron‑overloaded accelerates organ injury and raises mortality risk. 4, 5

In α‑thalassemia silent or minor carriers who are pregnant, true iron‑deficiency anemia may occur; oral iron (with ascorbic acid) can be trialed under close monitoring. 6
If oral therapy fails, intravenous iron may be used, but ferritin should be kept below 500 µg/L and hepcidin levels monitored dynamically to avoid inadvertent overload. 6

In transfusion‑dependent thalassemia major, the therapeutic focus should be on initiating or intensifying iron‑chelation regimens (deferoxamine, deferiprone, or deferasirox) rather than providing any form of iron supplementation. 7

Routine cardiac T2 MRI is advised to detect early cardiac iron deposition; a T2 value < 20 ms signals clinically significant overload. 8
Patients with cardiac T2* < 6 ms have an estimated 47 % risk of developing heart failure within one year and should receive aggressive chelation therapy comparable to that given for overt heart failure. 8

Serum ferritin should be regularly monitored during chelation therapy and maintained below 500 µg/L (mg/L) to avoid iron‑related toxicity, especially in children and adolescents. 9